CRISPR-Cas: Discovery, Function and Application

A special issue of Bioengineering (ISSN 2306-5354).

Deadline for manuscript submissions: closed (15 January 2021) | Viewed by 11909

Special Issue Editors


E-Mail Website
Guest Editor
Doudna Lab, University of California, Berkeley, USA
Interests: CRISPR; microbiology; biochemistry; gene regulation; epigenetics

E-Mail Website
Guest Editor
Doudna Lab, University of California, Berkeley, USA
Interests: CRISPR; microbiology; structural biology; biochemistry
Liu Lab, Harvard University/Broad Institute, Cambridge, MA, USA
Interests: genome engineering; CRISPR; protein evolution

Special Issue Information

CRISPR-Cas is a prokaryotic defense system that provides its host with an adaptive immunity against invading mobile genetic elements. These systems generally function by detecting foreign DNA or RNA based on complementarity to a small non-coding RNA guide to trigger a variety of nucleic acid degradation patterns for host protection. CRISPR-Cas systems are highly diverse in nature and recent efforts to optimize these systems through molecular engineering have converted CRISPR-Cas into a programmable “swiss-army” toolkit for biotechnological, therapeutic and diagnostic applications. With the increasing precision and safety of editing, CRISPR-Cas is not only being used for regular research but is also slowly approaching application in the clinic. In this special issue we will be interested but not limited to the following topics:

  • Evolution and discovery of CRISPR-Cas systems
  • Mechanisms of CRISPR-Cas function
  • Natural regulation and control mechanisms of CRISPR activity
  • Protein and RNA engineering approaches to achieve fine control of CRISPR-Cas activity
  • Development of CRISPR-Cas based technologies for novel applications
  • New and improved methods for the delivery of CRISPR tools
  • Advances in alternative methods for genome editing

Dr. Haridha Shivram
Dr. Patrick Pausch
Dr. Xin D. Gao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 2998 KiB  
Article
CRISPR/Cas9-Based Lateral Flow and Fluorescence Diagnostics
by Mark J. Osborn, Akshay Bhardwaj, Samuel P. Bingea, Friederike Knipping, Colby J. Feser, Christopher J. Lees, Daniel P. Collins, Clifford J. Steer, Bruce R. Blazar and Jakub Tolar
Bioengineering 2021, 8(2), 23; https://doi.org/10.3390/bioengineering8020023 - 12 Feb 2021
Cited by 24 | Viewed by 11085
Abstract
Clustered regularly interspaced short palindromic repeat (CRISPR/Cas) proteins can be designed to bind specified DNA and RNA sequences and hold great promise for the accurate detection of nucleic acids for diagnostics. We integrated commercially available reagents into a CRISPR/Cas9-based lateral flow assay that [...] Read more.
Clustered regularly interspaced short palindromic repeat (CRISPR/Cas) proteins can be designed to bind specified DNA and RNA sequences and hold great promise for the accurate detection of nucleic acids for diagnostics. We integrated commercially available reagents into a CRISPR/Cas9-based lateral flow assay that can detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences with single-base specificity. This approach requires minimal equipment and represents a simplified platform for field-based deployment. We also developed a rapid, multiplex fluorescence CRISPR/Cas9 nuclease cleavage assay capable of detecting and differentiating SARS-CoV-2, influenza A and B, and respiratory syncytial virus in a single reaction. Our findings provide proof-of-principle for CRISPR/Cas9 point-of-care diagnosis as well as a scalable fluorescent platform for identifying respiratory viral pathogens with overlapping symptomology. Full article
(This article belongs to the Special Issue CRISPR-Cas: Discovery, Function and Application)
Show Figures

Figure 1

Back to TopTop